Autumn Glory Partners LLC Takes $218,000 Position in Royalty Pharma PLC (NASDAQ:RPRX)

Autumn Glory Partners LLC bought a new stake in Royalty Pharma PLC (NASDAQ:RPRX) during the 1st quarter, Holdings Channel reports. The fund bought 7,000 shares of the biopharmaceutical company’s stock, valued at approximately $218,000.

Other hedge funds also recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Royalty Pharma by 4.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company’s stock worth $79,888,000 after acquiring an additional 130,025 shares during the period. Jupiter Asset Management Ltd. bought a new stake in Royalty Pharma in the fourth quarter worth approximately $4,950,000. Truist Financial Corp acquired a new stake in Royalty Pharma in the fourth quarter valued at approximately $371,000. Vontobel Holding Ltd. acquired a new stake in Royalty Pharma in the fourth quarter valued at approximately $230,000. Finally, New South Capital Management Inc. boosted its position in shares of Royalty Pharma by 19.9% during the fourth quarter. New South Capital Management Inc. now owns 2,957,125 shares of the biopharmaceutical company’s stock valued at $75,436,000 after buying an additional 490,754 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

RPRX stock opened at $34.91 on Thursday. Royalty Pharma PLC has a 1 year low of $24.05 and a 1 year high of $35.38. The stock’s fifty day moving average price is $33.00 and its 200-day moving average price is $31.09. The company has a market cap of $19.63 billion, a P/E ratio of 18.87, a price-to-earnings-growth ratio of 1.77 and a beta of 0.48. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.56 and a quick ratio of 1.56.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.99 by $0.07. Royalty Pharma had a return on equity of 24.71% and a net margin of 48.23%. The company had revenue of $839.00 million during the quarter, compared to analyst estimates of $724.69 million. On average, equities analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date was Friday, May 16th. Royalty Pharma’s dividend payout ratio (DPR) is presently 47.57%.

Analysts Set New Price Targets

Several research analysts have weighed in on RPRX shares. Citigroup reissued a “buy” rating on shares of Royalty Pharma in a research report on Friday, March 28th. Wall Street Zen cut Royalty Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, May 20th. Finally, Morgan Stanley assumed coverage on Royalty Pharma in a report on Friday, May 16th. They issued an “overweight” rating and a $51.00 price objective for the company. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $47.33.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.